-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Reiterates Outperform on BridgeBio Pharma, Maintains $106 Price Target

Benzinga·04/28/2026 14:39:09
Listen to the news
Mizuho analyst Salim Syed reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and maintains $106 price target.